TGFβ1-IN-4
TGFβ1-IN-4 is a TGF-β1 inhibitor. TGFβ1-IN-4 inhibits myofibroblast activation and epithelial-mesenchymal transition in vitro. TGFβ1-IN-4 alleviates renal fibrosis in a mouse model of renal fibrosis. TGFβ1-IN-4 can be used for research on fibrotic diseases such as renal fibrosis.
For research use only. We do not sell to patients.
- Formula: C51H83N13O13S2
- Molecular Weight:1150.41
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
TGFβ1-IN-4 (Peptide 27) (1-10 μM, 24-48 h) inhibits myofibroblast activation, fibrosis progression and epithelial-mesenchymal transition (EMT) in TGF-β1-induced NIH-3T3 and HK-2 cells[1].
TGFβ1-IN-4 (0-72 h) exhibits strong enzymatic hydrolysis resistance in mouse serum[1].
TGFβ1-IN-4 (1 mM) binds to albumin, as determined by isothermal titration calorimetry[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:NIH-3T3 cells treated with TGF-β1
-
Concentration:1, 2, 5, 10 μM
-
Incubation Time:48 h
-
Result:Reduced the expression of
fibronectin and α-SMA in a dose-dependent manner.
Suppressed the expression of collagen I, MMP2, and vimentin.
-
Cell Line:NIH-3T3 cells treated with TGF-β1
-
Concentration:1, 2 μM
-
Incubation Time:48 h
-
Result:Decreased expression levels of fibrosis-related genes, including fibronectin, collagen I, MMP2, vimentin, α-SMA, and TGF-β1.
-
Cell Line:HK-2 cells treated with TGF-β1
-
Concentration:1, 2, 5, 10 μM
-
Incubation Time:24 h
-
Result:Significantly inhibited the expression of fibronectin and α-SMA.
Reduced the expression of collagen I, MMP2, and vimentin while increasing the expression of E-cadherin.
-
Cell Line:HK-2 cells treated with TGF-β1
-
Concentration:1, 5 μM
-
Incubation Time:24 h
-
Result:Demonstrated consistent improvement effects on
the mRNA levels of fibrosis-related genes.
| Species | Dose | Route | T1/2 | AUC0-t | AUC0-∞ | CL | Vd | MRT |
|---|---|---|---|---|---|---|---|---|
| Mice[1] | 2.8 mg/kg | i.v. | 1.077 h | 1.894 μg·h/mL | 1.938 μg·h/mL | 0.028 L/h | 0.044 L | 0.337 h |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice (male, 20-25 g)[1]
-
Dosage:0.05, 0.25, 1.25 mg/kg
-
Administration:i.p.; daily; 7 days
-
Result:Improved kidney condition.
Prevented the formation of kidney inflammation and fibrosis. Dose-dependently reduced ECM deposition and the expression of fibrosis marker mRNA.
Mitigated the progression of epithelial-mesenchymal transition (EMT).
Reduced UUO-induced renal fibrosis in mice within a dose range of 0.05 to 1.25 mg/kg.
Chemical Information
-
Molecular Weight 1150.41
-
Formula C51H83N13O13S2
-
Sequence
C12-{d-Asp}-His-Asn-Cys-Pro-Gln-{d-Ala}-Cys-NH2 (Hexanedithiol linker:Cys4-Cys8)
-
Sequence Shortening
C12-{d-Asp}-HNCPQ-{d-Ala}-C-NH2 (Hexanedithiol linker:Cys4-Cys8)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TGFβ1-IN-4 Related Classifications
HY-P11609 Related Classifications
Powered by Bioz